DARWIN EU® Prevalence of rare blood cancers in Europe

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50801
• EU PAS number:
  EUPAS50800
• Study ID:
  50801
• Official title and acronym:
  DARWIN EU® Prevalence of rare blood cancers in Europe
• DARWIN EU® study:
  Yes
• Study countries:
  Belgium

  Germany

  Netherlands

  Spain

  United Kingdom
• Study description:
  In this study the prevalence of rare blood cancers (follicular lymphoma, diffuse large B-Cell lymphoma, multiple myeloma, chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia) will be assessed.
• Study status:
  Finalised

Research institution and networks

Institutions

Department of Medical Informatics - Health Data Science, Erasmus Medical Center (ErasmusMC)

Netherlands

Real-World-Evidence, IQVIA NL

Netherlands

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

University of Oxford

Networks

Data Analysis and Real World Interrogation Network (DARWIN EU®)

Belgium

Croatia

Denmark

Estonia

Finland

France

Germany

Hungary

Netherlands

Norway

Portugal

Spain

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 13/05/2022

Actual: 13/05/2022

Study start date

Planned: 01/11/2022

Actual: 01/11/2022

Date of final study report

Planned: 28/03/2023

Actual: 28/03/2023

Sources of funding

EMA

Study protocol

Initial protocol

D2.2.3_DARWIN_EU_Study Protocol C1-001_v2.0_EU_PAS

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable